Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash & Current Investments (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Cash & Current Investments for 7 consecutive years, with $639.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments fell 5.46% to $639.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $639.4 million through Dec 2025, down 5.46% year-over-year, with the annual reading at $639.4 million for FY2025, 5.46% down from the prior year.
  • Cash & Current Investments hit $639.4 million in Q4 2025 for IDEAYA Biosciences, down from $786.9 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $920.0 million in Q3 2024 to a low of $246.8 million in Q4 2021.
  • Historically, Cash & Current Investments has averaged $498.6 million across 5 years, with a median of $481.2 million in 2023.
  • Biggest five-year swings in Cash & Current Investments: skyrocketed 244.08% in 2021 and later dropped 16.45% in 2022.
  • Year by year, Cash & Current Investments stood at $246.8 million in 2021, then skyrocketed by 47.84% to $364.8 million in 2022, then surged by 43.93% to $525.1 million in 2023, then rose by 28.79% to $676.3 million in 2024, then decreased by 5.46% to $639.4 million in 2025.
  • Business Quant data shows Cash & Current Investments for IDYA at $639.4 million in Q4 2025, $786.9 million in Q3 2025, and $669.7 million in Q2 2025.